Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
01 September 2025 | Story Tshepo Tsotetsi | Photo Dr Reabetswe Parkies
BAccHons and PGDip graduates
Prof Frans Prinsloo, Head of the UFS School of Accountancy, with some of the proud 2024 BAccHons and PGDip (Chartered Accountancy) graduates who contributed to the School’s outstanding 96% pass rate in the June 2025 Initial Assessment of Competence (IAC).

The University of the Free State (UFS) has once again affirmed its position as one of the country’s leading institutions in accounting education. In the June 2025 Initial Assessment of Competence (IAC) by the South African Institute of Chartered Accountants (SAICA), UFS graduates from the 2024 BAccHons and PGDip (Chartered Accountancy) programmes achieved an exceptional 96% pass rate. This performance stands well above the national throughput of 76% across both the January and June sittings, confirming the university’s reputation for producing work-ready Chartered Accountants (CAs).

This achievement in the IAC – previously known as the Initial Test of Competence (ITC) – not only showcases the quality of teaching and learning at UFS but also echoes the recent SAICA endorsement visit, during which evaluators commended the School of Accountancy for cultivating confident, competent graduates ready to contribute to both the profession and the South African economy.

 

Driving excellence through vision and innovation

Reflecting on the results, Prof Frans Prinsloo, Head of the School of Accountancy, emphasised that this success confirms the School’s long-standing commitment to excellence and innovation. “Exceeding the national average by such a significant margin reinforces that our programmes are developing highly competent and sought-after Chartered Accountants. This achievement places UFS among the leading institutions in South Africa for producing high-quality graduates,” he said.

Prof Prinsloo attributed the outcome to the unwavering dedication of staff who, as highlighted by SAICA’s endorsement team, “go above and beyond” to support student success. He also pointed to a range of initiatives that have created an enabling environment for achievement, from a humanising pedagogy that prioritises student voices and dynamic learning communities, to early intervention strategies and an academic trainee programme that provides peer support through consultations and small-group sessions. “We are not just delivering a curriculum; w are fostering a culture of learning, growth, and achievement,” Prof Prinsloo added.

Prof Phillipe Burger, Dean of the Faculty of Economic and Management Sciences, said the results reflect the faculty’s broader vision of preparing leaders who can excel in both business and society. “We are preparing leaders for tomorrow, and education is the key to that. Corporate leadership requires technical expertise, but also resilience, adaptability, and the ability to work as part of a team. All of this we pack into our CA programme,” he explained.

Prof Burger also highlighted the faculty’s national role in shaping the profession through ongoing collaboration with SAICA and industry, ensuring that graduates remain relevant and highly employable. He noted the remarkable growth in the faculty’s accounting programmes, with the BAcc enrolling four times as many new first-year students this year compared to five years ago, alongside a significant increase in the average Admission Point (AP) scores of incoming students. “This growth, combined with rising admission standards, is testament to the quality of our programmes and the confidence that students and parents have in what we offer,” Prof Burger said.

As UFS celebrates this milestone, both leaders agree that the achievement belongs not only to the graduates but to the entire learning community. The outstanding 96% pass rate signals the university’s continued success in producing Chartered Accountants who are academically excellent, ethically grounded, and ready to make an impact in South Africa and beyond.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept